ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,554.25
      0.20%
      US Tech 100
      18,971.20
      -0.03%
      Dow Jones
      40,659.76
      0.24%
      Brent Oil
      79.165
      0.00%
      Bitcoin
      59,568.10
      0.16%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      08/16/20245:59AMBusiness WireIncyte gibt positive Topline-Ergebnisse der Pivotalstudie mit Tafasitamab (Monjuvi®) bei rezidiviertem oder refraktärem follikulärem Lymphom bekanntNASDAQ:INCYIncyte Corporation
      08/16/20245:46AMBusiness WireIncyte annonce des résultats positifs de l'étude pivot sur le tafasitamab (Monjuvi®) dans le lymphome folliculaire récidivant ou réfractaireNASDAQ:INCYIncyte Corporation
      08/15/20244:30PMBusiness WireIncyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular LymphomaNASDAQ:INCYIncyte Corporation
      08/15/20244:15PMBusiness WireIncyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)NASDAQ:INCYIncyte Corporation
      08/15/20246:26AMBusiness WireIncyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)NASDAQ:INCYIncyte Corporation
      08/14/20245:34PMBusiness WireIncyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)NASDAQ:INCYIncyte Corporation
      08/14/20243:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      08/13/20248:00AMBusiness WireIncyte to Present at Upcoming Investor ConferencesNASDAQ:INCYIncyte Corporation
      08/12/20244:39PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      08/07/20245:00PMBusiness WireIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
      07/30/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
      07/30/20247:00AMBusiness WireIncyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
      07/29/20243:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/25/20244:09PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      07/24/20242:20PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:INCYIncyte Corporation
      07/17/202412:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/17/202412:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/17/202412:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/17/202412:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/17/202412:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/17/202412:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/17/202412:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/17/202412:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/17/202412:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/17/202412:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/16/20244:36PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      07/11/202412:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/09/20244:32PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      07/09/20248:00AMBusiness WireIncyte to Report Second Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
      07/08/20244:30PMBusiness WireIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY